GPX4 protein degradation agent based on hydrophobic label as well as preparation method and application of GPX4 protein degradation agent

By designing a hydrophobic label-based GPX4 protein degrader, the compound structure is used to induce misfolding of GPX4 protein, targeted degradation is achieved, the toxicity and easy off-target problems of existing inhibitors are solved, and significant anti-proliferative and degradable activities are demonstrated. It has potential anti-tumor treatment value.

CN118994147AActive Publication Date: 2024-11-22OCEAN UNIV OF CHINA

Patent Information

Application Number
CN202410962265.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-22
Estimated Expiration
2044-07-18

AI Technical Summary

Technical Problem

The existing GPX4 inhibitors have problems such as high toxicity, poor pharmacokinetics and easy off-targeting, and the principle of action of hydrophobic label degradation technology is still unclear, which limits its application in ferrodynamic treatment.

Method used

A hydrophobic tag-based GPX4 protein degrader was developed to mimic the degradation of the protein quality control system by synthesizing specific compound structures to achieve targeted degradation, providing a new anti-tumor drug selection.

Benefits of technology

It showed significant anti-proliferative activity and GPX4 degradation activity on HT1080 cells, which was better than the existing inhibitor RSL3, and had better market application prospects and could be used as a target for the development of new anti-tumor drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994147A_ABST
    Figure CN118994147A_ABST
Patent Text Reader

Abstract

The invention discloses a GPX4 protein degradation agent based on a hydrophobic label and a preparation method and application thereof, and belongs to the technical field of medicines, and the structural general formula of the GPX4 protein degradation agent based on the hydrophobic label and pharmaceutically acceptable salts of the GPX4 protein degradation agent is shown as (I). Pharmacological experiments show that the compound provided by the invention has very strong anti-proliferative activity on ferroptosis sensitive cells HT1080, and can effectively down-regulate the GPX4 protein level in the HT1080 cells. The compound disclosed by the invention has an application value of a GPX4 degradation agent, can be applied to preparation of anti-tumor medicines, and has a good market application prospect. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to a GPX4 protein degradation agent based on a hydrophobic tag, and a preparation method and application thereof. Background Art

[0002] In 2012, the Stockwell research group proposed the concept of "ferroptosis". As a new form of cell death, ferroptosis is an iron-dependent, programmed cell death caused by lipid peroxidation accumulation. Ferroptosis in the human body is closely related to many diseases such as cancer and neurodegenerative diseases. Regulating ferroptosis may be a potential breakthrough in the treatment of these diseases. In the study of the mechanism of ferroptosis, it was found that the cystine\glutamate antiporter system (Xc-)-glutathione peroxidase 4 (Glutathione peroxidase 4, GPX4) axis is an important component of ferroptosis defense. Among them, GPX4 can use glutathione to reduce toxic lipid peroxides to non-toxic alcohols, thereby avoiding ferroptosis. Studies have shown that inhibiting the function of GPX4 can induce ferroptosis.

[0003] GPX4 is a selenoprotein with selenocysteine ​​(Sec) as its catalytic center. The drug binding pocket discovered so far is a shallow pocket on the surface of the protein, so inhibitors targeting GPX4 usually carry covalently bound warheads, which exert their inhibitory effects by irreversibly covalently binding to selenocysteine, the active center of GPX4. However, these inhibitors generally have the disadvantages of high toxicity, poor pharmacokinetics, and easy off-target effects.

[0004] In recent years, targeted protein degradation (TPD) has developed rapidly. Compared with traditional small molecule inhibitors, TPD drugs have the advantages of being able to rapidly degrade target proteins, allowing protein site mutations, breaking through undruggable targets, and reducing drug resistance. Therefore, transforming small molecule drugs into corresponding degraders may break through the shortcomings of the drugs or targets themselves, thereby bringing more ideal results. A research group designed a PROTAC degrader based on GPX4 inhibitors, and experiments have shown that it can target and induce GPX4 downregulation. Hydrophobic tags are an emerging targeted degradation technology. By linking a large hydrophobic fragment to the target protein ligand with a suitable linker, when the target protein ligand recognizes the target protein, a hydrophobic fragment is introduced on the protein surface to simulate protein misfolding, thereby causing the target protein to be degraded by the protein quality control system. Compared with PROTAC, it maintains the advantages of targeted protein degradation technology, has a smaller molecular weight, and has no potential teratogenicity risk. However, the specific mechanism of action of hydrophobic tag degradation technology is still unknown, so the expansion and application of this technology is urgently needed, which is conducive to the development and improvement of hydrophobic tag degradation technology. Summary of the invention

[0005] The purpose of the present invention is to provide a GPX4 protein degrader based on a hydrophobic tag, and a preparation method and application thereof. The present invention provides the activity screening results of a GPX4 degrader based on a hydrophobic tag on ferroptosis-sensitive cells HT1080 and its application as a GPX4 degrader, and experiments prove that the compound of the present invention can be used as a GPX4 degrader for the preparation of anti-tumor drugs.

[0006] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0007] The first aspect of the present invention provides a GPX4 protein degrader based on a hydrophobic tag and a pharmaceutically acceptable salt thereof, which has a structure as shown in the following formula (1):

[0008]

[0009] Wherein, R1 is selected from the following groups:

[0010]

[0011] X is selected from the following linking groups:

[0012]

[0013] n is 1 to 20, and m is 1 to 20.

[0014] Further preferably, the compound of the general formula I is the following compound:

[0015] Compound R-A1: (1S,3R)-1-(4-((2-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)ethoxy)ethyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0016] Compound R-A2: (1S,3R)-1-(4-((2-(2-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0017] Compound R-A3: (1S, 3R)-1-(4-((1-((3R, 5R, 7R)-adamantan-1-yl)-2-oxo-6,9,12-trioxa-3-azatetradecane-14-yl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0018] Compound R-B1: (1S,3R)-1-(4-((2-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)ethyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0019] Compound R-B2: (1S,3R)-1-(4-((4-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)butyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0020] Compound R-B3: (1S,3R)-1-(4-((5-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)pentyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0021] Compound R-B4: (1S,3R)-1-(4-((6-(2-((3R,5R,7R)-adamantan-1-yl)acetamido)hexyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0022] Compound R-B5: (1S,3R)-1-(4-((7-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)heptyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0023] Compound R-B6: (1S,3R)-1-(4-((8-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)octyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0024] Compound R-B7: (1S,3R)-1-(4-((10-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)decyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0025] Compound R-C1: (1S, 3R)-1-(4-(4-(2-((3R, 5R, 7R)-adamantan-1-yl)acetyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0026] Compound R-C2: (1S,3R)-1-(4-(4-(2-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)ethyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0027] Compound R-C3: (1S,3R)-1-(4-(4-(4-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)butyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0028] Compound R-C4: (1S,3R)-1-(4-(4-(6-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)hexyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0029] Compound R-C5: (1S,3R)-1-(4-(4-(8-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)octyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0030] Compound R-C6: (1S, 3R)-2-acryloyl-1-(4-(4-(6-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)hexyl)piperazine-1-carbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester;

[0031] Or compound R-C7: (1S, 3R)-1-(4-(4-(6-(2-((3r, 5r, 7r)-adamantan-1-yl)acetylamino)hexyl)piperazine-1-carbonyl)phenyl)-2-propioloyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester.

[0032] Further preferably, the pharmaceutically acceptable salt is an inorganic acid salt or an organic acid salt; the inorganic acid is selected from at least one of hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; the organic acid is selected from at least one of methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, maleic acid or succinic acid, fumaric acid, salicylic acid, phenylacetic acid, and mandelic acid.

[0033] The second aspect of the present invention provides a method for preparing the hydrophobic tag-based GPX4 protein degrader and a pharmaceutically acceptable salt thereof, the preparation method comprising the following steps:

[0034] (1) Synthetic intermediates

[0035] p-Formaldehyde benzoic acid 1 reacts with Boc2O to generate intermediate 2; intermediate 2 is cyclized with D-tryptophan formate hydrochloride 3 to obtain intermediate 4;

[0036]

[0037] (2) Synthetic compounds

[0038] Intermediate 4 reacts with oxygen chain 5a-5c to generate intermediate 6a-6c through condensation reaction; intermediate 6a-6c is deprotected by Boc using TFA and then condensed with adamantane acetic acid 7 to obtain intermediate 8a-8c; finally, intermediate 8a-8c reacts with chloroacetyl chloride 9 to obtain target compounds R-A1 to R-A3;

[0039]

[0040] Alternatively, intermediate 4 is reacted with alkane chain 10a-10g to generate intermediate 11a-11g through condensation reaction; intermediate 11a-11g is deprotected by Boc using TFA and then condensed with adamantane acetic acid 7 to obtain intermediate 12a-12g; finally, intermediate 12a-12g is reacted with chloroacetyl chloride 9 to obtain target compounds R-B1 to R-B7;

[0041]

[0042] Alternatively, intermediate 4 reacts with N-Boc-piperazine to generate intermediate 14 through condensation reaction; intermediate 14 is deprotected by Boc using TFA and then condensed with adamantane acetic acid 7 to obtain intermediate 15; finally, intermediate 15 reacts with chloroacetyl chloride 9 to obtain the target compound R-C1;

[0043]

[0044] Furthermore, the preparation method also includes the synthesis of compounds R-C2 to R-C5:

[0045] Dibromoalkanes of different lengths react with isoindoline-1,3-dione 16 in the presence of K2CO3 to obtain intermediates 17a-17d; intermediates 17a-17d react with N-Boc-piperazine 13 in the presence of K2CO3 to obtain intermediates 18a-18d; intermediates 18a-18d are first reduced under the action of 85% hydrazine hydrate and then react with adamantane acetic acid 7 to obtain intermediates 19a-19d; intermediates 19a-19d and intermediate 4 are respectively deprotected from Boc protecting groups in TFA, and the obtained products are then condensed with each other to obtain intermediates 20a-20d; finally, intermediates 20a-20d react with chloroacetyl chloride 9 to obtain target compounds R-C2 to R-C5, intermediate 20c reacts with acryloyl chloride 21 to obtain target compound R-C6, and intermediate 20c reacts with propiolic acid 22 to obtain target compound R-C7;

[0046]

[0047] The present invention provides the use of the hydrophobic tag-based GPX4 protein degrader and a pharmaceutically acceptable salt thereof in the preparation of a GPX4 protein inhibitor.

[0048] The third aspect of the present invention provides the use of the hydrophobic tag-based GPX4 protein degrader and a pharmaceutically acceptable salt thereof in the preparation of anti-tumor drugs.

[0049] Furthermore, the tumor is a ferroptosis-sensitive tumor, including human breast cancer, human fibrosarcoma and renal cancer.

[0050] Compared with the prior art, the advantages and technical effects of the present invention are as follows: the newly synthesized hydrophobic tag-based GPX4 protein degrader of the present invention was tested for in vitro antitumor activity on HT1080 cells, and the relevant data are shown in Table 2, with the GPX4 inhibitor RSL3 reported in the literature as the positive drug. Experiments have shown that the newly synthesized hydrophobic tag-based GPX4 protein degrader of the present invention exhibits significant antiproliferative activity on HT1080 cells. Among them, the activities of compounds such as R-B4, R-B5, and R-C1 are better than the positive drug RSL3, and they have further research value and can be used for further development.

[0051] The results of the protein immunoblotting experiment of the newly synthesized GPX4 degrader based on the hydrophobic tag technology on HT1080 cells are shown in Table 3 and Figure 1 As shown. Compounds with similar activity to RSL3 were further selected at two concentrations of 0.05μM and 0.02μM. At the same concentration, compounds R-B4, R-B5 and other compounds showed better GPX4 degradation activity than RSL3, while R-C1 with better activity at 0.02μM had already shown better GPX4 degradation activity than RSL3 at 0.2μM, which also corresponded to their activities, proving that the improved activity of the compound was due to the enhanced degradation of GPX4.

[0052] Experiments have shown that the hydrophobic tag-based GPX4 protein degrader provided by the present invention has significant anti-proliferation activity and GPX4 degradation activity on HT1080 cells. The compound of the present invention has application value as a GPX4 degrader, can be used in the preparation of anti-tumor drugs, and has good market application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 Representative results of GPX4 degradation activity of compound R-C1 on HT1080 cells. DETAILED DESCRIPTION

[0054] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0055] The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or conditions recommended by the manufacturer. The percentages described in the examples are all weight percentages unless otherwise specified.

[0056] The specific compound structural formula and NMR data of the GPX4 protein degrader provided by the present invention are shown in Table 1 below:

[0057] Table 1. Structural formula and NMR data of the compounds provided by the present invention

[0058]

[0059]

[0060]

[0061]

[0062]

[0063] Example 1: Preparation of (1S,3R)-1-(4-(tert-butyloxycarbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester 4

[0064] (1) Preparation of intermediate 2: tert-butyl 4-formylbenzoate

[0065] The raw material p-formylbenzoic acid 1 (1g, 6.66mmol) was dissolved in 10mL THF, and Boc2O (2.91g, 3.06mL, 13.32mmol,) and DMAP (162.8mg, 1.33mmol) were added, and the reaction was carried out at 80°C for 2h. After TLC detection, the reaction solution was quenched with 10mL saturated NaHCO3, and the aqueous layer was extracted with dichloromethane (50mL×3). The combined organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (PE:EA=20:1) to obtain 800mg of colorless oily liquid, which was intermediate 2, with a yield of 60%. 1 H NMR (400MHz, Chloroform-d) δ: 10.08 (s, 1H), 8.16–8.12 (m, 2H), 8.07 (d, J = 8.4Hz, 1H), 7.93–7.91 (m, 1H), 1.61 (s, 9H).

[0066] (2) Preparation of Intermediate 4: (1S, 3R)-1-(4-(tert-butyloxycarbonyl)phenyl)-2,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylic acid methyl ester

[0067] D-tryptophan methyl ester hydrochloride (1.16 g, 4.54 mmol) was added to 20 mL of DCM, and TEA (497.8 mg, 684 μL, 4.92 mmol) was added. The mixture was stirred at room temperature for 1 h to dissolve all the residues. The solvent was evaporated to dryness under reduced pressure and then dried. The dried product was dissolved in 30 mL of DCM. Intermediate 2 (780 mg, 3.78 mmol) and TFA (43.1 mg, 28 μL, 0.38 mmol) were added, and the mixture was reacted at 45 °C for 1 h. TFA (1.29 g, 843 μL, 11.4 mmol) was added, and the mixture was reacted at 45 °C for 8 h. The reaction was completed by TLC detection, and the reaction solution was quenched with 20 mL of saturated NaHCO3, and the aqueous layer was extracted with dichloromethane (100 mL × 3). The combined organic layers were dried over anhydrous Na 2 SO 4 , concentrated under reduced pressure, and purified by silica gel column chromatography (PE:EA=4:1) to obtain 351 mg of a white solid, Intermediate 4, with a yield of 23%. 1 H NMR(400MHz,Chloroform-d)δ:7.94(d,J=8.2Hz,2H),7.58–7.53(m,2H),7.35(d,J=8.2Hz,2H),7.26–7.22(m,1H),7.15( pd,J=7.0,1.1Hz,2H),5.47(s,1H),3.96(t,J=6.0Hz,1H),3.72(s,3H),3.21(ddd,J=50.8,15.4,6.4Hz,2H),1.58(s,9H).

[0068]

[0069] Reagents and conditions: a: DMAP, Boc2O, THF, 80℃, 2h, yield 60%. b: TEA, TFA, DCM, 45℃, 10h, yield 23%.

[0070] Example 2: Preparation of (1S, 3R)-1-(4-((2-(2-((3R, 5R, 7R)-adamantan-1-yl)acetylamino)ethoxy)ethyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester R-A1

[0071] (1) Preparation of Intermediate 6a: (1S,3R)-1-(4-((2-((tert-butyloxycarbonyl)amino)ethoxy)ethyl)ethyl)carbamoyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester

[0072] Intermediate 4 (100 mg, 0.25 mmol) was dissolved in 4 mL DCM, 2 mL TFA was added, and the reaction was carried out at room temperature for 2 h. After TLC detection, the reaction was completed, the solvent was evaporated under reduced pressure, and it was directly put into the next step without purification. The crude product was dissolved in 4 mL DMF, HBTU (139.9 mg, 0.37 mmol) and DIPEA (47.7 mg, 64 μL, 0.37 mmol) were added, stirred for 5 minutes, and compound 5a (55.3 mg, 0.27 mmol) was added, and the reaction was carried out at room temperature for 8 h. After TLC detection, the reaction was completed, 100 mL saturated NaCl solution was added, and the aqueous layer was extracted with ethyl acetate (50 mL×3). The combined organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (DCM: MeOH = 50: 1) to obtain 55 mg of a yellow solid, which was intermediate 6a, with a yield of 42%. 1 H NMR(400MHz,Chloroform-d)δ:7.84–7.70(m,2H),7.54(d,J=7.4Hz,1H),7.33 (d,J=7.1Hz,2H),7.17–7.09(m,2H),6.60(s,1H),5.44(s,1H),4.84(s,1H),3. 93(t,J=5.5Hz,1H),3.71(s,3H),3.63(d,J=8.2Hz,4H),3.53(t,J=5.3Hz,2H) ,3.30(d,J=7.5Hz,2H),3.24(d,J=5.0Hz,1H),3.18–3.08(m,1H),1.39(s,9H).

[0073] (2) Preparation of Intermediate 8a: (1S,3R)-1-(4-((2-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)ethoxy)ethyl)carbamoyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester

[0074] Compound 6a (55 mg, 0.1 mmol) was dissolved in 4 mL DCM, 2 mL TFA was added, and the mixture was reacted at room temperature for 2 h. After TLC detection, the reaction was completed, the solvent was evaporated under reduced pressure, and the mixture was directly put into the next step without purification. The crude product was dissolved in 4 mL DMF, HBTU (56.2 mg, 0.15 mmol) and DIPEA (19.1 mg, 26 μL, 0.15 mmol) were added, stirred for 5 minutes, and compound 7 (21.1 mg, 0.11 mmol) was added, and the mixture was reacted at room temperature for 8 h. After TLC detection, 100 mL saturated NaCl solution was added, and the aqueous layer was extracted with ethyl acetate (50 ml × 3). The combined organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (DCM: MeOH = 100: 3) to obtain 20 mg of a yellow solid, which was intermediate 8a, with a yield of 33%. 1 H NMR(400MHz,Chloroform-d)δ:7.82(s,1H),7.74(d,J=8.2Hz,2H),7.54(d,J=7.3Hz,1H),7.33(d,J= 8.2Hz,2H),7.23(s,1H),7.14(dtd,J=14.4,7.1,1.2Hz,2H),6.68(s,1H),5.79(t,J=5.2Hz,1H),5.4 5(s,1H),3.94(t,J=6.0Hz,1H),3.71(s,3H),3.62(d,J=2.1Hz,4H),3.54(t,J=5.1Hz,2H),3.41(q,J =5.3Hz,2H),3.30–3.10(m,2H),1.88(d,J=8.8Hz,5H),1.64(d,J=12.1Hz,3H),1.55(d,J=2.4Hz,9H).

[0075] (3) Preparation of target compound R-A1:

[0076] Compound 8a (20 mg, 0.03 mmol) was dissolved in 5 mL DCM, TEA (5 mg, 7 μL, 0.05 mmol) was added, and compound 9 (5.5 mg, 4 μL, 0.05 mmol) was diluted in 1 ml DCM under 0 °C ice bath conditions, and then slowly added to the above reaction system, and slowly warmed to room temperature for 10 h. After the reaction was completed by TLC detection, 50 mL of saturated NaCl solution was added, and the aqueous layer was extracted with dichloromethane (20 mL×3). The combined organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (DCM: MeOH = 100: 3) to obtain 17 mg of a white solid, which was compound R-A1, with a yield of 76%. 1H NMR(400MHz,Chloroform-d)δ:8.75(d,J=69.1Hz,1H),7.67(d,J=68.0Hz,2H),7.50(d, J=8.3Hz,1H),7.30(s,1H),7.19(s,1H),7.09(p,J=6.9Hz,2H),6.80(d,J=116.8Hz,1H) ,6.14(d,J=43.3Hz,1H),5.90(s,1H),5.20(s,1H),4.08(d,J=31.2Hz,2H),3.57(d,J=4 5.6Hz,14H),1.87(d,J=11.6Hz,5H),1.66(d,J=13.0Hz,3H),1.62(s,2H),1.53(s,7H). 13 C NMR (400MHz, DMSO) δ172.20,170.50,168.26,166.63,147.37,136.90,134.31,133.37,128.35,127.72,127.09,126.20,126.12,12 1.81,119.36,118.52,111.80,104.03,69.48,69.21,57.05,56.52,53.27,50.44,43.80,42.52,38.79,36.89,32.59,28.48,26.82.

[0077]

[0078] Reagents and conditions: a: (1) TFA, DCM, rt, 4h, yield 100%. (2) HBTU, DIPEA, rt, 8h, yield 20-95%. b: (1) TFA, DCM, rt, 4h, yield 100%. (2) HBTU, DIPEA, rt, 8h, yield 20-95%.c:TEA,DCM,rt,8h,yield40-85%.

[0079] Example 3

[0080] Preparation of compound R-A2: Compound 5a in the first step of Example 2 was replaced by compound 5b, and the rest was the same as Example 2 to prepare compound R-A2 with a yield of 30%.

[0081] Example 4

[0082] Preparation of compound R-A3: Compound 5a in the first step of Example 2 was replaced by compound 5c, and the rest was the same as Example 2 to prepare compound R-A3 with a yield of 33%.

[0083] Example 5

[0084] Preparation of compound R-B1: Compound 5a in the first step of Example 2 was replaced by compound 10a, and the rest was the same as Example 2 to prepare compound R-B1 with a yield of 37%.

[0085] Example 6

[0086] Preparation of compound R-B2: Compound 5a in the first step of Example 2 was replaced by compound 10b, and the rest was the same as Example 2 to prepare compound R-B2 with a yield of 31%.

[0087] Example 7

[0088] Preparation of compound R-B3: Compound 5a in the first step of Example 2 was replaced by compound 10c, and the rest was the same as Example 2 to prepare compound R-B3 with a yield of 39%.

[0089] Example 8

[0090] Preparation of compound R-B4: Compound 5a in the first step of Example 2 was replaced by compound 10d, and the rest was the same as Example 2 to prepare compound R-B4 with a yield of 37%.

[0091] Example 9

[0092] Preparation of compound R-B5: Compound 5a in the first step of Example 2 was replaced by compound 10e, and the rest was the same as Example 2 to prepare compound R-B5 with a yield of 34%.

[0093] Example 10

[0094] Preparation of compound R-B6: Compound 5a in the first step of Example 2 was replaced by compound 10f, and the rest was the same as Example 2 to prepare compound R-B6 with a yield of 38%.

[0095] Embodiment 11

[0096] Preparation of compound R-B7: Compound 5a in the first step of Example 2 was replaced by compound 10g, and the rest was the same as Example 2 to prepare compound R-B7 with a yield of 35%.

[0097]

[0098] Reagents and conditions: a: (1) TFA, DCM, rt, 4h, yield 100%. (2) HBTU, DIPEA, rt, 8h, yield 20-95%. b: (1) TFA, DCM, rt, 4h, yield 100%. (2) HBTU, DIPEA, rt, 8h, yield 20-95%.c:TEA,DCM,rt,8h,yield40-85%.

[0099] Example 12

[0100] Preparation of compound R-C1: Compound 5a in the first step of Example 2 was replaced by compound 13, and the rest was the same as Example 2 to prepare compound R-C1 with a yield of 26%.

[0101]

[0102] Reagents and conditions: a: (1) TFA, DCM, rt, 4h, yield 100%. (2) HBTU, DIPEA, rt, 8h, yield 89%. b: (1) TFA, DCM, rt, 4h, yield 100%. (2), HBTU, DIPEA, rt, 8h, yield 84%. c: TEA, DCM, rt, 8h, yield 62%.

[0103] Embodiment 13

[0104] Preparation of (1S,3R)-1-(4-(4-(2-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)ethyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester R-C2

[0105] (1) Preparation of intermediate 17a: 2-(2-bromoethyl)isoindoline-1,3-dione

[0106] Compound 16 (500 mg, 3.4 mmol) was dissolved in 15 mL of DMF, 1,2-dibromoethane (957.6 mg, 440 μL, 5.1 mmol) and K2CO3 (1.41 g, 10.2 mmol) were added, and the mixture was stirred at room temperature overnight. After the reaction was completed by TLC, 200 mL of saturated NaCl solution was added, and the aqueous layer was extracted with ethyl acetate (50 mL×3). The combined organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (PE:EA=10:1) to obtain 828 mg of a white solid, which was intermediate 17a, with a yield of 96%. 1H NMR (400MHz, Chloroform-d) δ7.86(dt,J=7.3,3.6Hz,2H),7.76–7.71(m,2H),4.10(t,J=6.7Hz,2H),3.61(t,J=6.7Hz,2H).

[0107] (2) Preparation of Intermediate 18a: tert-butyl 4-(2-(1,3-dioxoisoindolin-2-yl)ethyl)piperazine-1-carboxylate

[0108] Intermediate 17a (828 mg, 3.26 mmol) was dissolved in 20 mL of acetonitrile, and N-Boc-piperazine 13 (728.6 mg, 3.91 mmol), K2CO3 (1.13 g, 8.15 mmol) and 3 drops of TEA were added, and the mixture was heated to reflux at 85°C for 8 h. After TLC detection, the reaction was completed, and the mixture was first concentrated under reduced pressure, and then extracted with water and dichloromethane. The obtained organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (DCM:MeOH=30:1) to obtain 837 mg of a yellow oil, which was intermediate 18a, with a yield of 72%. 1 H NMR(400MHz,Chloroform-d)δ7.82(td,J=5.2,2.0Hz,2H),7.71(td,J=5.5,5.1,1.9Hz,2H),3. 81(t,J=6.4Hz,2H),3.39–3.30(m,4H),2.63(t,J=6.4Hz,2H),2.49–2.38(m,4H),1.43(s,9H).

[0109] (3) Preparation of Intermediate 19a: tert-butyl 4-(2-(2-((3R, 5R, 7R)-adamantan-1-yl)acetylamino)ethyl)piperazine-1-carboxylate

[0110] The intermediate 18a (400 mg, 1.11 mmol) was dissolved in 25 mL of anhydrous ethanol, and 85% hydrazine hydrate (841 mg, 964 μL, 16.7 mmol) was added, and refluxed at 80 ° C for 5 h. The reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. 100 mL of dichloromethane was added, and washed with water (30 mL×3). The obtained organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The obtained crude product was directly put into the next step without further purification. The crude product (225 mg, 0.98 mmol) was dissolved in 8 mL of DMF, and adamantane acetic acid 7 (229.1 mg, 1.18 mmol), HBTU (558.9 mg, 1.47 mmol) and DIPEA (190.5 mg, 257 μL, 1.47 mmol) were added, and stirred at room temperature overnight. After the reaction was completed by TLC detection, 200 mL of saturated NaCl solution was added, and the aqueous layer was extracted with ethyl acetate (50 mL×3). The combined organic layers were dried over anhydrous Na 2 SO 4 , concentrated under reduced pressure, and purified by silica gel column chromatography (DCM:MeOH=100:3) to obtain 220 mg of a yellow solid as Intermediate 19a in a yield of 57%. 1 H NMR (400MHz, Chloroform-d) δ3.54–3.34(m,6H),2.72–2.35(m,6H),1.96(d,J=4.4Hz,5H),1.70(d,J=12.2Hz,3H),1.61(d,J=2.2Hz,9H),1.46(s,9H).

[0111] (4) Preparation of Intermediate 20a: (1S,3R)-1-(4-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetylamino)ethyl)piperazine-1-carbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester

[0112] Compound 4 (50 mg, 0.12 mmol) was dissolved in 4 mL DCM, 2 mL TFA was added, and the mixture was reacted at room temperature for 2 h. After the reaction was completed by TLC, the solvent was evaporated to dryness under reduced pressure and directly used in the subsequent reaction without purification. Intermediate 19a (59.9 mg, 0.15 mmol) was dissolved in 4 mL DCM, 2 mL TFA was added, and the mixture was reacted at room temperature for 2 h. After the reaction was completed by TLC, the solvent was evaporated to dryness under reduced pressure and directly used in the subsequent reaction without purification. The two crude products obtained above were mixed and dissolved in 5 mL DMF, HBTU (70 mg, 0.18 mmol) and DIPEA (23.8 mg, 33 μL, 0.18 mmol) were added, and the mixture was stirred at room temperature overnight. After the reaction was completed by TLC, 100 mL saturated NaCl solution was added, and the aqueous layer was extracted with ethyl acetate (30 mL×3). The combined organic layers were dried over anhydrous Na 2 SO 4 , concentrated under reduced pressure, and purified by silica gel column chromatography (DCM:MeOH=25:2) to obtain 67 mg of a yellow solid as Intermediate 20a in a yield of 85%. 1 H NMR(400MHz,Chloroform-d)δ7.65(s,1H),7.56(d,J=7.2Hz,1H),7.35(d,J=2.2Hz ,4H),7.25(s,1H),7.20–7.10(m,2H),5.43(s,1H),3.97(t,J=6.0Hz,1H),3.73(s, 5H),3.45(s,2H),3.36(q,J=5.5Hz,2H),3.31–3.24(m,1H),3.19–3.11(m,1H),2.5 9–2.39(m,6H),1.95(d,J=10.0Hz,5H),1.70(d,J=12.3Hz,3H),1.64–1.60(m,9H).

[0113] (5) Preparation of target compound R-C2

[0114] The intermediate 20a (67 mg, 0.11 mmol) was dissolved in 5 mL DCM, TEA (17.8 mg, 13 μL, 0.16 mmol) was added, and compound 9 (15.9 mg, 23 μL, 0.16 mmol) was diluted in 1 ml DCM under 0 ° C ice bath conditions, and then slowly added to the above reaction system, slowly warmed to room temperature and reacted for 10 h. After TLC detection, the reaction was completed, 50 mL of saturated NaCl solution was added, and the aqueous layer was extracted with dichloromethane (20 mL × 3). The combined organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (DCM: MeOH = 25: 2) to obtain 60 mg of a white solid, which was compound R-C2, with a yield of 80%. 1H NMR(400MHz,Chloroform-d)δ8.28(s,1H),7.56–7.28(m,5H),7.11(q,J=7.7,6.8Hz,3H),6.30–5.96(m,1H),5.77(s,1H),5.19(s,1H),4 .22–3.98(m,2H),3.65(s,7H),3.49–3.30(m,5H),2.56–2.36(m,6H),1.95(d,J=10.2Hz,5H),1.70(d,J=12.2Hz,3H),1.64–1.61(m,9H). 13 C NMR (400MHz, DMSO) δ172.18,170.31,169.15,168.27,145.61,136.86,134.49,127.54,127.33,126.33,126.24,121.81,119.40,118. 53,111.89,104.06,57.30,57.09,56.49,53.28,50.60,43.84,42.57,36.94,36.21,32.62,31.45,28.51,26.82,22.56,14.45,11.74.

[0115] Embodiment 14

[0116] Preparation of compound R-C3: Replace the first step compound 1,2-dibromoethane in Example 13 with compound 1,4-dibromobutane, and proceed with the same procedures as Example 13 to obtain compound R-C3 with a yield of 41%.

[0117] Embodiment 15

[0118] Preparation of compound R-C4: Replace the first step compound 1,2-dibromoethane in Example 13 with compound 1,6-dibromohexane. The rest is the same as Example 13 to prepare compound R-C4 with a yield of 40%.

[0119] Example 16

[0120] Preparation of compound R-C5: Replace the first step compound 1,2-dibromoethane in Example 13 with compound 1,8-dibromooctane. The rest is the same as Example 13 to prepare compound R-C5 with a yield of 45%.

[0121] Embodiment 17

[0122] Preparation of (1S, 3R)-2-acryloyl-1-(4-(4-(6-(2-((3r, 5r, 7r)-adamantan-1-yl)acetylamino)hexyl)piperazine-1-carbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester R-C6

[0123] The intermediate 20a (100 mg, 0.14 mmol) was dissolved in 5 mL DCM, and DIPEA (22.4 mg, 30 μL, 0.17 mmol) and DMAP (9 mg, 0.07 mmol) were added. Acryloyl chloride 21 (15.6 mg, 14 μL, 0.17 mmol) was diluted in 1 ml DCM under ice bath conditions, and then slowly added to the above reaction system, and slowly warmed to room temperature for 8 hours. After the reaction was completed by TLC detection, 50 mL of saturated NaCl solution was added, and the aqueous layer was extracted with dichloromethane (20 mL×3). The combined organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (DCM: MeOH = 25:2) to obtain 77 mg of a white solid, which was compound R-C6, with a yield of 71%. 1 H NMR(400MHz,Chloroform-d)δ:7.52–7.28(m,5H),7.10(q,J=7.3Hz,3H),6.39(dd,J=16.8, 10.1Hz,1H),6.14(d,J=65.1Hz,1H),5.88(dd,J=16.8,2.3Hz,1H),5.78(dd,J=10.1,2.4Hz ,1H),5.30(s,1H),5.18(s,1H),4.3–3.4(m,10H),3.21(m,2H),2.52(d,J=69.2Hz,6H),1.9 8(s,3H),1.89(s,2H),1.63(d,J=10.1Hz,3H),1.61(m,9H),1.50–1.47(m,4H),1.29(s,4H). 13 C NMR(101MHz,DMSO)δ173.11,172.52,170.35,168.88,137.52,136.81,13 4.53,132.90,127.96,127.92,127.83,127.73,127.20,122.28,119.91, 118.62,111.32,106.63,56.54,54.53,53.03,52.95,52.73,46.00,45.7 9,40.20,38.61,36.28,35.24,30.11,28.62,27.69,27.37,25.88,22.35.

[0124] Embodiment 18

[0125] Preparation of (1S,3R)-1-(4-(4-(6-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)hexyl)piperazine-1-carbonyl)phenyl)-2-propioloyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester R-C7

[0126] The intermediate 20a (100 mg, 0.14 mmol) was dissolved in 10 mL DCM, propiolic acid 22 (20.2 mg, 18 μL, 0.29 mmol), CMPI (88.4 mg, 0.35 mmol) and TEA (70 mg, 99 μL, 0.69 mmol) were added, and the reaction was carried out at room temperature for 8 h. After the reaction was completed by TLC detection, 50 mL of saturated NaCl solution was added, and the aqueous layer was extracted with dichloromethane (20 mL×3). The combined organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (DCM: MeOH = 25: 2) to obtain 26 mg of a white solid, which was compound R-C7, with a yield of 24%. 1 H NMR(400MHz,Chloroform-d)δ8.22(s,1H),7.57–7.30(m,4H),7.23–7.04(m,4H) ),6.13(d,J=75.9Hz,1H),5.37(s,1H),5.19(s,1H),4.20–3.78(m,4H),3.68–3. 32(m,7H),3.24–3.18(m,2H),2.52(d,J=47.8Hz,6H),1.95(s,3H),1.89(s,2H), 1.69(d,J=12.0Hz,3H),1.61(d,J=10.5Hz,9H),1.54–1.46(m,4H),1.32(s,4H). 13 C NMR (101MHz, DMSO) δ173.11,172.52,170.35,161.27,137.52,136.81,134.53,132.87,127.91,127.83,127.20,122.28,119.91,118.62,111.32 ,106.63,77.52,76.79,56.54,54.82,52.95,52.73,52.25,46.00,45.79 ,40.20,38.61,36.28,35.24,30.11,28.62,27.69,27.37,25.88,22.35.

[0127]

[0128] Reagents and conditions: a: K2CO3, DMF, rt, 8h, yield 71%. b: K2CO3, TEA, CH3CN, 85℃, 8h, yield 89%. c: (1): hydrazine hydrate, CH3CH2OH, 80℃, 4h, yield 100%. (2): HBTU, DIPEA, DMF, rt, 8h, yield 70-95%.d:(1)TFA,DCM,rt,4h,yield 100%.(2)HBTU,DIPEA,rt,8h,40-60%.e:TEA,DCM,0℃,8h,yield40-85%.f:ac-ryloyl chloride,DIPEA,DMAP,0℃,8h,yield71%.g:propiolic acid,CMPI,TEA,rt,8h,yield24%.

[0129] Example 19: In vitro antitumor activity test of target compounds (IC 50 )

[0130] The compounds of the present invention were tested for their anti-proliferation ability on HT1080 cells (human fibrosarcoma cells) using the SRB method. HT1080 cells in the logarithmic growth phase were digested with trypsin, and then diluted and suspended into a single cell suspension using a culture medium (DMEM + 10% FBS + 1% double antibody), and the cell density was adjusted to 3-4×10 4 / mL, add 90μL of cell suspension to each well of a 96-well plate, place in a 37℃, 5% CO2 incubator for 24 hours, and observe under a microscope to confirm that the cells are well attached. Add 10μL of culture medium containing samples of different concentrations, three replicate wells for each concentration, and set up corresponding DMSO control groups for each, and continue incubating in a 5% CO2, 37℃ incubator for 72h. Shake off the culture medium, first fix with 100μL TCA, place in a 4℃ refrigerator for at least 1h, remove the fixative, wash along the edge of the plate with tap water 5-6 times, dry at 50℃ (2h), add 100μL SRB to each well, keep it away from light for 10min, and remove unbound SRB. Wash three times with 1% glacial acetic acid, dry (50℃, 2h), then add 100-150μL of non-buffered tris alkali solution to dissolve the bound SRB, shake steadily for 2min, and mix well. The cells were placed on an enzyme-linked immunosorbent assay instrument and the optical density (OD) of each well was measured at a wavelength of 515 nm. The experiment was repeated 3 times. The survival rate was calculated according to the following formula: % survival rate = OD value of the experimental group / OD value of the DMSO control group × 100%.

[0131] Experimental results: The half inhibitory concentration IC of the compounds of the present invention on HT1080 cells 50 As shown in Table 2, most of the B series compounds with methylene as linker and C series compounds with piperazine rigid ring as linker have better antitumor activity than the positive control RSL3. Among the different covalently bound warhead compounds, the activity of propynamide warhead R-C7 is better than that of chloroacetamide warhead R-C4 and acrylamide warhead R-C6. Compound R-C1 has the best antitumor activity (0.005±0.001μM), which is about 18 times better than RSL3 (0.090±0.010μM).

[0132] Table 2 In vitro antitumor activity of target compounds

[0133]

[0134] Example 20: GPX4 degradation activity test of target compound

[0135] The compounds of the present invention were tested for GPX4 degradation activity on HT1080 cells by protein immunoblotting. HT1080 cells in the logarithmic growth phase were inoculated on a 6-well plate at a density of 300,000 / well, 1800 μL per well, and cultured in an incubator at 37°C and 5% CO2. The control group was DMSO, and after co-culture with different concentrations of the compounds of the present invention for 24 hours, PBS was washed twice, and appropriate Loading Buffer was added to each well, and the cells were lysed at 4°C for 45 minutes. After the lysis was completed, the cells were collected in a centrifuge tube with a clean cell scraper and boiled in boiling water for 15 minutes. The proteins were separated by 10% SDS-PAGE and transferred to the NC membrane. The membrane was washed with TBST, incubated with blocking solution for 30 minutes, and then incubated with the primary antibody after washing with TBST, and gently shaken overnight at 4°C. The membrane was washed with TBST and incubated with the secondary antibody at room temperature for 2 hours. Rinse and develop the image, and the obtained protein blot image was processed and analyzed using Image J software.

[0136] Experimental results: The degradation effects of some compounds of the present invention on GPX4 in HT1080 cells are shown in Table 3, among which the degradation activities of R-B1, R-B4~B5, R-B7, and R-C4~C7 are better than the positive drug RSL3. Corresponding to the fact that these compounds are better than RSL3, it can be proved that the improvement in the activity of these compounds is due to the enhanced degradation effect on GPX4. Since the activity of R-C1 is significantly better than other compounds, a lower concentration was further selected to test its degradation effect on GPX4. Four concentration gradients of 0.001, 0.005, 0.01, and 0.02 μM were set respectively, so as to more accurately judge its degradation effect on GPX4. Results are shown in Figure 1The results showed that compound R-C1 could degrade GPX4 in a concentration-dependent manner, and the degradation rate reached 83±2% at a concentration of 0.02 μM.

[0137] Table 3 GPX4 degradation activity of target compounds

[0138]

[0139] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with this patent can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.

Claims

1. A GPX4 protein degrader based on a hydrophobic tag or a pharmaceutically acceptable salt thereof, characterized in that: It has the structure shown in the following formula (1): Wherein R1 is selected from the following groups: X is selected from the following linking groups: n is 1 to 20, and m is 1 to 20.

2. The GPX4 protein degrading agent or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: It is the following compound: Compound R-A1: (1S,3R)-1-(4-((2-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)ethoxy)ethyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-A2: (1S,3R)-1-(4-((2-(2-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-A3: (1S, 3R)-1-(4-((1-((3R, 5R, 7R)-adamantan-1-yl)-2-oxo-6,9,12-trioxa-3-azatetradecane-14-yl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-B1: (1S,3R)-1-(4-((2-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)ethyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-B2: (1S,3R)-1-(4-((4-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)butyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-B3: (1S,3R)-1-(4-((5-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)pentyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-B4: (1S,3R)-1-(4-((6-(2-((3R,5R,7R)-adamantan-1-yl)acetamido)hexyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-B5: (1S,3R)-1-(4-((7-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)heptyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-B6: (1S,3R)-1-(4-((8-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)octyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-B7: (1S,3R)-1-(4-((10-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)decyl)carbamoyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-C1: (1S, 3R)-1-(4-(4-(2-((3R, 5R, 7R)-adamantan-1-yl)acetyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-C2: (1S,3R)-1-(4-(4-(2-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)ethyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-C3: (1S,3R)-1-(4-(4-(4-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)butyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-C4: (1S,3R)-1-(4-(4-(6-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)hexyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-C5: (1S,3R)-1-(4-(4-(8-(2-((3R,5R,7R)-adamantan-1-yl)acetylamino)octyl)piperazine-1-carbonyl)phenyl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Compound R-C6: (1S, 3R)-2-acryloyl-1-(4-(4-(6-(2-((3r, 5r, 7r)-adamantan-1-yl)acetamido)hexyl)piperazine-1-carbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester; Or compound R-C7: (1S, 3R)-1-(4-(4-(6-(2-((3r, 5r, 7r)-adamantan-1-yl)acetylamino)hexyl)piperazine-1-carbonyl)phenyl)-2-propioloyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester.

3. The GPX4 protein degrading agent or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The pharmaceutically acceptable salt is an inorganic acid salt or an organic acid salt; the inorganic acid is selected from at least one of hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; the organic acid is selected from at least one of methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, maleic acid or succinic acid, fumaric acid, salicylic acid, phenylacetic acid, and mandelic acid.

4. The method for preparing the GPX4 protein degrading agent or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The preparation method comprises the following steps: (1) Synthetic intermediates p-Formaldehyde benzoic acid 1 reacts with Boc2O to generate intermediate 2; intermediate 2 is cyclized with D-tryptophan formate hydrochloride 3 to obtain intermediate 4; (2) Synthetic compounds Intermediate 4 reacts with oxygen chain 5a-5c to generate intermediate 6a-6c through condensation reaction; intermediate 6a-6c is deprotected by Boc using TFA and then condensed with adamantane acetic acid 7 to obtain intermediate 8a-8c; finally, intermediate 8a-8c reacts with chloroacetyl chloride 9 to obtain target compounds R-A1 to R-A3; Alternatively, intermediate 4 is reacted with alkane chain 10a-10g to generate intermediate 11a-11g through condensation reaction; intermediate 11a-11g is deprotected by Boc using TFA and then condensed with adamantane acetic acid 7 to obtain intermediate 12a-12g; finally, intermediate 12a-12g is reacted with chloroacetyl chloride 9 to obtain target compounds R-B1 to R-B7; Alternatively, intermediate 4 reacts with N-Boc-piperazine to generate intermediate 14 through condensation reaction; intermediate 14 is deprotected by Boc using TFA and then condensed with adamantane acetic acid 7 to obtain intermediate 15; finally, intermediate 15 reacts with chloroacetyl chloride 9 to obtain the target compound R-C1; 5. The preparation method according to claim 4, characterized in that: The step (2) also includes: Dibromoalkanes of different lengths react with isoindoline-1,3-dione 16 in the presence of K2CO3 to obtain intermediates 17a-17d; intermediates 17a-17d react with N-Boc-piperazine 13 in the presence of K2CO3 to obtain intermediates 18a-18d; intermediates 18a-18d are first reduced and then reacted with adamantane acetic acid 7 to obtain intermediates 19a-19d; intermediates 19a-19d and intermediate 4 are respectively deprotected from Boc protecting groups in TFA, and the obtained products are then condensed with each other to obtain intermediates 20a-20d; finally, intermediates 20a-20d react with chloroacetyl chloride 9 to obtain target compounds R-C2 to R-C5, intermediate 20c reacts with acryloyl chloride 21 to obtain target compound R-C6, and intermediate 20c reacts with propiolic acid 22 to obtain target compound R-C7; 6. Intermediate 2 and intermediate 4 obtained in step (1) of the preparation method according to claim 4.

7. Use of the GPX4 protein degrading agent or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3 in the preparation of a GPX4 protein inhibitor.

8. Use of the GPX4 protein degrading agent or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3 in the preparation of an anti-tumor drug.

9. The use according to claim 8, characterized in that: The tumor is a ferroptosis-sensitive tumor.

10. The use according to claim 9, characterized in that: The ferroptosis-sensitive tumors include human breast cancer, human fibrosarcoma and renal cancer.

Citation Information

Patent Citations

  • Compound with ferroptosis inducing activity and method thereof

    CN112041301A

  • Compounds with ferroptosis inducing activity and methods of their use

    CN114008024A

  • Ferroptosis inhibitor based on multi-component reaction as well as preparation method and application of ferroptosis inhibitor

    CN117327068A

  • Compounds and methods of use

    WO2021041539A2

  • Glutathione peroxidase 4 (GPX4) inhibitors for the treatment of cancer

    WO2024015637A1

Cited By

  • Compound for degrading Pol theta based on hydrophobic label as well as preparation method and application of compound

    CN119823115A